HIV resistance and the developing world

International Journal of Antimicrobial Agents

Volumn 29, Issue 5, 2007, Pages 510-517

  Gupta, Ravindra Kumar ^a   Pillay, Deenan ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiretrovirals; ART; Developing world; HAART; HIV; Public health; Resistance; Virology

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; MK 0518; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDUSTRIALIZATION; PRIORITY JOURNAL; SHORT SURVEY; UNSPECIFIED SIDE EFFECT;

ANTI-HIV AGENTS; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; VARIATION (GENETICS); VIRUS REPLICATION;

EID: 34147145457     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.01.003     Document Type: Short Survey

References (70)

1. Palella Jr. F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338 (1998) 853-860
2. Joint United Nations Programme on HIV/AIDS. AIDS epidemic update, December 2005 (2005), UNAIDS/WHO, Geneva. http://data.unaids.org/Publications/IRC-pub06/epi_update2005_en.pdf [accessed 25 November 2006]
3. Kantor R., Shafer R.W., Follansbee S., et al. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS 18 (2004) 1503-1511
4. World Health Organisation. ARV treatment guidelines and technical and operational recommendations for ART. http://www.who.int/3by5/publications/briefs/oms09arvguidelines.pdf [accessed 25 November 2006].
5. Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., and Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373 (1995) 123-126
6. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., and Ho D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life span and viral generation time. Science 271 (1996) 1582-1586
7. Wei X., Ghosh S.K., Taylor M.E., et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373 (1995) 117-122
8. Roberts J.D., Bebenek K., and Kunkel T.A. The accuracy of reverse transcriptase from HIV-1. Science 242 (1988) 1171-1173
9. Preston B.D., Poiesz B.J., and Loeb L.A. Fidelity of HIV-1 reverse transcriptase. Science 242 (1988) 1168-1171
10. Phillips A.N., Dunn D., Sabin C., et al., UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 19 (2005) 487-494
11. Parikh U.M., Barnas D.C., Faruki H., and Mellors J.W. Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. J Infect Dis 194 (2006) 651-660
12. Gallant J.E., Staszewski S., Pozniak A.L., et al., 903 Study Group. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292 (2004) 191-201
13. Gallant J.E., DeJesus E., Arribas J.R., et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354 (2006) 251-260
14. Hsoiu Y., Ding J., Das K., et al. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J Mol Biol 309 (2001) 437-445
15. Boyer P.L., Currens M.J., MacMahon J.B., et al. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J Virol 67 (1993) 2412-2420
16. Witrouw M., Pannecouque C., Van Laethem K., et al. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS 13 (1999) 1477-1483
17. Shih C.K., Rose J.M., Hansen G.L., Wu J.C., Bacolla A., and Griffin J.A. Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors. Proc Natl Acad Sci USA 88 (1991) 9878-9882
18. Vingerhoets J, Peeters M, Corbett C, et al. Effect of baseline resistance on the virologic response to a novel NNRTI, TMC125, in patients with extensive NNRTI and PI resistance: analysis of study TMC125-223. In: Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections, 2006. Denver, CO [abstract 154].
19. Havlir D.V., Eastman S., Gamst A., and Richman D.D. Nevirapine resistance in HIV-1: kinetics of replication and estimated prevalence in untreated patients. J Virol 70 (1996) 7894-7899
20. Jackson J.B., Becker-Pergola G., Guay L.A., et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent vertical transmission. AIDS 14 (2000) F111-F115
21. Conway B., Wainberg M.A., Hall D., et al. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS 15 (2001) 1269-1274
22. McIntyre JA, Martinson N, Gray GE, et al. Addition of short course Combivir (CBV) to single dose Viramune (sdNVP) for the prevention of mother to child transmission (MTCT) of HIV-1 can significantly decrease the subsequent development of maternal and paediatric NNRTI-resistant virus. In: 3rd IAS Conference on HIV Pathogenesis and Treatment; 24-27 July, 2005. Rio de Janeiro, Brazil. [abstract no. WePe4.4C11]
23. Mackie N.E., Fidler S., Tamm N., et al. Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance. HIV Med 5 (2004) 180-184
24. Erickson-Viitanen S., Manfredi J., Viitanen P., et al. Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res Hum Retroviruses 5 (1989) 577-591
25. Kumar G.N., Rodrigues A.D., Buko A.M., and Denissen J.F. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277 (1996) 423-431
26. Hicks C.B., Cahn P., Cooper D.A., et al., RESIST Investigator Group. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 368 (2006) 466-475
27. Baxter J.D., Schapiro J.M., Boucher C.A., et al. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 80 (2006) 10794-10801
28. Lazzarin A, Queiroz-Telles F, Frank I, et al. TMC114 provides durable viral load suppression in treatment-experienced patients: POWER 1 and 2 combined week 48 analysis. In: Proceedings of the XVI International AIDS Conference, 13-18 August 2006. Toronto, Canada [abstract TUAB0104].
29. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2006. http://www.iasusa.org/resistance_mutations/mutations_figures.pdf [accessed 25 November 2006].
30. Lu J., Deeks S.G., Hoh R., et al. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr 43 (2006) 60-64
31. Dorr P., Westby M., Dobbs S., et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49 (2005) 4721-4732
32. McHale M, Abel S, Russell D, Gallagher J, van der Ryst E. Overview of phase 1 and 2a safety and efficacy data of maraviroc (UK-427,857). In: Proceedings of the 3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005. Rio de Janeiro, Brazil [abstract TuOa0204 (oral)].
33. van der Ryst E, Mayer H, Goodrich JM, et al. Selective suppression of R5 HIV-1 by the novel CCR5 antagonist maraviroc (MVC) is associated with maintenance of CD4 cell counts in antiretroviral-experienced patients (pts) infected with dual/mixed-tropic (D/M) HIV-1. In: Proceedings of the 8th International Congress on Drug Therapy in HIV Infection, 12-16 November 2006. Glasgow, UK [P393].
34. Westby M., Lewis M., Whitcomb J., et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 80 (2006) 4909-4920
35. Markowitz M, Nguyen B-Y, Gotuzzo E, et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, as part of combination ART in treatment-naive HIV-1 infected patients. In: Proceedings of the XVI International AIDS Conference, 13-18 August 2006. Toronto, Canada [late breaker abstract THLB0214].
36. Grinsztejn B, Nguyen B, Katlama C, et al. Potent efficacy of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus: 24-week data. In: Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 27-30 September 2006. San Francisco, CA [abstract H-1670b].
37. Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. In: Proceedings of the 15th International Workshop on HIV Drug Resistance, 2006. Sitges, Spain [abstract 23].
38. WHO expert working group meeting to determine preferred ARV medicines for treating and preventing HIV infection in younger children. October 23-25, 2006. Meeting report http://www.who.int/hiv/events/paediatricmeetingreport.pdf [accessed 23 January 2007].
39. Kellam P., and Larder B. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 38 (1994) 23-30
40. Hertogs K., de Bethune M.P., Miller V., et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 42 (1998) 269-276
41. Petropoulos C.J., Parkin N.T., Limoli K.L., et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 44 (2000) 920-928
42. Frater A.J., Beardall A., Ariyoshi K., et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS 15 (2001) 1493-1502
43. Weidle P.J., Malamba S., Mwebaze R., et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 360 (2002) 34-40
44. Pillay D., Walker A.S., Gibb D.M., et al. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect Dis 186 (2002) 617-625
45. Frater A.J., Dunn D.T., Beardall A.J., et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 24 16 (2002) 1139-1146
46. Descamps D., Apetrei C., Collin G., Damond F., Simon F., and Brun-Vezinet F. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. AIDS 12 (1998) 1109-1111
47. Abecasis A.B., Deforche K., Snoeck J., et al. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS 19 (2005) 1799-1806
48. Kantor R., Katzenstein D.A., Efron B., et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2 (2005) e112
49. Cane P.A., de Ruiter A., Rice P., Wiselka M., Fox R., and Pillay D. Resistance-associated mutations in the human immunodeficiency virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom. J Clin Microbiol 39 (2001) 2652-2654
50. Gonzalez L.M., Brindeiro R.M., Aguiar R.S., et al. Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases. Antimicrob Agents Chemother 48 (2004) 3552-3555
51. Eshleman S.H., Hoover D.R., Chen S., et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 192 (2005) 30-36
52. Gupta R.K., Chrystie I.L., O'Shea S., Mullen J.E., Kulasegaram R., and Tong C.Y. K65R and Y181C are less prevalent in HAART-experienced HIV-1 subtype A patients. AIDS 19 (2005) 1916-1919
53. Wainberg MA, Doualla-Bell F, Gaolathe T, Madisa M, Essex M, Brenner B. HIV-1 subtype C viruses rapidly develop K65R resistance against ddI and tenofovir. In: Proceedings of the 8th International Congress on Drug Therapy in HIV Infection, 12-16 November 2006. Glasgow, UK [PL3.4].
54. Brenner B., Turner D., Oliveira M., et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 17 (2003) F1-F5
55. Morris L., Pillay C., Chezzi C., et al. Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine. AIDS 17 (2003) 1698-1700
56. Dumans A.T., Soares M.A., Machado E.S., et al. Synonymous genetic polymorphisms within Brazilian HIV-1 subtypes may influence mutational routes to drug resistance. J Infect Dis 189 (2004) 1232-1238
57. Caride E., Hertogs K., Larder B., et al. Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virus Genes 23 (2001) 193-202
58. Grossman Z., Vardinon N., Chemtob D., et al. Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B. AIDS 15 (2001) 1453-1460
59. Loemba H., Brenner B., Parniak M.A., et al. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother 46 (2002) 2087-2094
60. Brindeiro P.A., Brindeiro R.M., Mortensen C., et al. Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy. J Clin Microbiol 40 (2002) 4512-4519
61. Pieniazek D., Rayfield M., Hu D.J., et al. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group. AIDS 14 (2000) 1489-1495
62. Kee KK, Kamarulzaman A, Ng KP. Low prevalence of genotypic drug resistance mutations among antiretroviral-naïve HIV-1 patients in Malaysia. In: Proceedings of the 3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005. Rio de Janeiro, Brazil [poster exhibition, abstract no. WePe4.1C05].
63. Si XF, Huang HL, Wei M, et al. Prevalence of genotypic resistance among drug-naïve HIV-1-infected patients in China. In: Proceedings of the XV International AIDS Conference, 11-16 July 2004. Bangkok, Thailand [abstract no. WePeB5735].
64. Almeida FJ, Berezin EN, Rodrigues R, et al. Diversity and prevalence of genotypic resistance mutations in HIV-1 infected children in Sáo Paulo, Brazil. In: Proceedings of the XV International AIDS Conference, 11-16 July 2004. Bangkok, Thailand [abstract no. B12115].
65. Agwale S, Tanimoto L, Womack C, et al. Primary antiretroviral resistance and molecular diversity of HIV-1 in antiretroviral therapy patients enrolled into the Nigerian national ART programme. In: Proceedings of the 3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005. Rio de Janeiro, Brazil [abstract no. WePe4.1C12].
66. Arora S, Sachdeva N. Increase in frequency of mutant variants of HIV-1 (subtype-C) carrying drug-resistance related mutations in pol-gene in treatment-naïve patients in North India. In: Proceedings of the XVI International AIDS Conference, 13-18 August 2006. Toronto, Canada [abstract no. CDB0417].
67. Bessong P, Mphahlele J, Obi L, Rekosh D, Hammerskjold ML. Baseline genetic drug resistance analysis of South African HIV-1 subtype C proteases. In: Proceedings of the 12th Conference on Retroviruses and Opportunistic Infections, 22-25 February 2005. Boston, MA.
68. Yarosh O, Jibril H, Rankopo O, et al. The analysis of genotypic resistance testing results of ARV-naïve children infected with HIV-1C in Botswana. In: Proceedings of the 3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005. Rio de Janeiro, Brazil [abstract no. WePe4.4C05].
69. Adje-Toure CA, Fassinou P, Borget MY, et al. Genotypic HIV-1 drug resistant strains among children receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. In: Proceedings of the XV International AIDS Conference, 11-16 July 2004. Bangkok, Thailand [abstract no. B10612].
70. DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 20 (2006) 1391-1399